Maynard Um
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) Tops Q2 EPS by 35c ; Offers Guidance
-
-
-
-
-
-
-
UBS Upgrades Corcept Therapeutics (CORT) to Neutral
-
-
-
-
-
-
-
FDA approves Corcept's relacorilant combination for platinum-resistant ovarian cancer
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) PT Raised to $105 at H.C. Wainwright
-
-
-
-
-
-
-
Wolfe Research Downgrades Corcept Therapeutics (CORT) to Underperform
-
-
-
-
-
-
-
Corcept submits European application for ovarian cancer treatment
-
-
-
-
-
-
-
Piper Sandler Reiterates OW Rating on Corcept Therapeutics (CORT) Following Expert Call
-
471,029 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


